Member Info for PL75

They're a distributor, so they'll be selling. I can't imagine they carry stock.

Good questions gmcc.... they've improved both top and bottom line. In ship shape for sale.

I’m not surprised to learn that. They’re dribbling morons. Best binned or ignored and reported.

This time it’s a retrospective trawl through the same old boring nonsense. Obviously expected cash so they’re playing catch up.

Having a go at breast cancer is universal enough I reckon. Package that up for a deal and then crack on with STS...

Don't worry about that, they just whack them over the content

They can barely put together a website

Cash. Who cares. Quarterly tedium.

Nice RNS today that’ll be more impactful in the long term.

Nice one smart @rse. Exatecan is under patent protection via derivatives and ADCs, that’s what it said. It provided sources. It didn’t wipe your backside for you.

No idea what you’re doing. Gpt4 searched the web and used avacta’s website as sources. Yours looks like a gpt3.5 response. You wasted your usage asking it for limericks about wynbore being a twat didn’t you?

Prompt: What's the partnership relationship between avacta and novartis? Can you include any sources

There doesn't appear to be a formal partnership between Avacta and Novartis. However, Avacta is advancing its oncology pipeline through its proprietary pre|CISION® technology, which includes the development of AVA6103. This asset is a peptide drug conjugate that delivers exatecan, a topoisomerase I inhibitor, specifically to tumors using a FAP-activated mechanism. This approach aims to reduce systemic toxicity associated with exatecan's use as a standalone agent.

The broader oncology landscape has seen many partnerships focusing on targeted drug delivery technologies similar to Avacta's, particularly in addressing challenges with toxicity and tumor targeting. This includes collaborations with major pharmaceutical companies like AstraZeneca and Daiichi Sankyo, who work on antibody-drug conjugates. Avacta's proprietary technology could potentially be an attractive asset for future collaborations, including with companies like Novartis or others seeking innovative cancer therapies.

For more details on Avacta's developments, see their recent pipeline expansions with AVA6103 and AVA7100【81†source】【82†source】.

There once was a fellow named Wynbore,

Whose antics were hard to ignore.

He'd rant and he'd spat,

Acting just like a twat,

Leaving folks rolling their eyes even more.

Here you are. Turns out he’s got terminal cancer too…

Once upon a time, in a kingdom far away, Prince Charming faced a daunting battle—he had been diagnosed with terminal cancer. The news spread across the land, casting a shadow over the once-bright kingdom. Despite his bravery, all traditional treatments had failed him.

Then, Avacta, a renowned healer with the power of science, arrived. She introduced a promising new potion, AVA6103, known for its ability to target illness with precision. The prince began his treatment, and slowly, his strength returned. Though the road was long and the outcome uncertain, Avacta’s magic brought hope to Prince Charming and his kingdom once more.

As the prince's condition improved, he realized that even in the darkest times, a glimmer of hope could shine through when science and courage joined forces. And so, Prince Charming continued his fight, side by side with Avacta, inspiring others to believe in the magic of possibility.

Irrelevant, but here you go…

AstraZeneca and Affibody Medical AB have collaborated on multiple projects, including an agreement where AstraZeneca's MedImmune division licensed Affibody's Albumod™ platform. This technology helps extend the half-life of therapeutic compounds, improving their effectiveness by allowing them to stay active in the body for longer periods. The partnership aimed to enhance the pharmacokinetic profiles of AstraZeneca's proprietary drug candidates. The Albumod™ platform is particularly valuable in biologic drug development, where optimizing the duration of action can significantly improve treatment outcomes【67†source】.

Btw, catch up. Everyone can access gpt4, but you get a limited number of prompts per day. Don’t waste them on fairy tales.

BIA beat me to it

Thanks for sharing

Notice BV hasn't corrected my posts. JV with DS to develop magic potions on the way. You heard it here first

Why does LSE allow this self promotion? Suepud regularly spams links to this cr.p and should be banned.

Yeah, I get all that, but we won't have a second asset in the clinic for a while. Feels more like they've chosen the pipeline as a shop window. Once they've got the data, assuming all is good, then deals will inevitably happen.

Part of your first quote:

"And so, these can take longer; they need more clinical data, even into Phase 2, and perhaps even a second asset in the clinic"

Why?

These posts are utterly stupid. They have one drug in the clinic in phase 1b for specific indications. WTF has that got to do with him. Yet someone said your posts were intelligent.

Incidentally I didn’t mention ava6103 in my prompt. So it must be true!

I asked ChatGPT to write a children’s story about avacta and DS:

Once upon a time in the magical world of Pharma Valley, there was a clever little company called Avacta. Avacta loved to invent special potions called "medicines" that could help people feel better. One day, while working in its enchanted lab, Avacta discovered a brilliant way to make potions even safer and stronger—it was called the "pre|CISION™ magic." This special magic allowed the potions to work only where they were needed, like finding the sick parts of the body and leaving the healthy parts alone!

But there was one challenge: Avacta knew it needed help to share its potions with all the people who needed them. So, Avacta looked for a brave and powerful partner who could journey far and wide across the land. That’s when it met Daiichi Sankyo, a mighty company known for helping many heroes fight fierce illnesses. Daiichi Sankyo had a vast network of healers, knights, and helpers who could carry Avacta's magic potions to every corner of the world.

Together, Avacta and Daiichi Sankyo formed a partnership, like two heroes combining their strengths. Avacta used its pre|CISION™ magic to create a special potion called AVA6103, designed to find and fight the most troublesome illnesses without causing harm to healthy parts of the body. Daiichi Sankyo, with its powerful wings and wide reach, helped bring AVA6103 to the people who needed it most, from the tallest mountains to the deepest valleys.

As the two partners worked together, they discovered they could help more people than ever before. The magical potion, AVA6103, began healing those who had lost hope, and it was all thanks to the friendship and teamwork between Avacta and Daiichi Sankyo.

And so, Avacta and Daiichi Sankyo continued their quest to make the world a healthier place, one potion at a time. Together, they proved that when friends join forces and share their magic, they can achieve wonderful things and bring light to the darkest corners.

And they lived happily ever after, curing illnesses and making Pharma Valley a brighter, healthier world for everyone.

Some time in 2026 then?